VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q56520992 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000048.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q56520992‏
024 ‎‡a 0000-0002-9422-0519‏ ‎‡2 orcid‏
024 ‎‡a 35310450700‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q56520992‏
100 0 ‎‡a Christopher J Hoffmann‏ ‎‡c researcher‏ ‎‡9 en‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Christopher J Hoffmann‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's A comparison of death recording by health centres and civil registration in South Africans receiving antiretroviral treatment‏
670 ‎‡a Author's A Framework to Inform Strategies to Improve the HIV Care Continuum in Low- and Middle-Income Countries‏
670 ‎‡a Author's A novel HIV treatment model using private practitioners in South Africa‏
670 ‎‡a Author's Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events‏
670 ‎‡a Author's Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme‏
670 ‎‡a Author's CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.‏
670 ‎‡a Author's CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa‏
670 ‎‡a Author's Changing predictors of mortality over time from cART start: implications for care‏
670 ‎‡a Author's Chronic hepatitis B increases mortality and complexity among HIV-coinfected patients in South Africa: a cohort study.‏
670 ‎‡a Author's Clinical implications of HIV and hepatitis B co-infection in Asia and Africa‏
670 ‎‡a Author's Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study‏
670 ‎‡a Author's Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV.‏
670 ‎‡a Author's Diagnostic accuracy of plasma kynurenine/tryptophan ratio, measured by enzyme-linked immunosorbent assay, for pulmonary tuberculosis‏
670 ‎‡a Author's Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study‏
670 ‎‡a Author's Effective Interpersonal Health Communication for Linkage to Care After HIV Diagnosis in South Africa‏
670 ‎‡a Author's Epidemiology of tuberculosis and HIV: recent advances in understanding and responses‏
670 ‎‡a Author's Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): study protocol for a cluster randomised controlled trial‏
670 ‎‡a Author's Factors Associated With Poor Linkage to HIV Care in South Africa: Secondary Analysis of Data From the Thol'impilo Trial‏
670 ‎‡a Author's Factors associated with pulmonary impairment in HIV-infected South African adults‏
670 ‎‡a Author's Feasibility of implementing same-day antiretroviral therapy initiation during routine care in Ekurhuleni District, South Africa: Retention and viral load suppression‏
670 ‎‡a Author's Four models of HIV counseling and testing: utilization and test results in South Africa‏
670 ‎‡a Author's Future of HIV/AIDS Care in Low- and Middle- Income Countries‏
670 ‎‡a Author's Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study‏
670 ‎‡a Author's Hepatitis B and long-term HIV outcomes in coinfected HAART recipients‏
670 ‎‡a Author's Hepatitis B Infection, Viral Load and Resistance in HIV-Infected Patients in Mozambique and Zambia‏
670 ‎‡a Author's Hepatitis B prevalence and treatment needs among Tibetan refugees residing in India.‏
670 ‎‡a Author's Hepatitis B virus infection and response to antiretroviral therapy‏
670 ‎‡a Author's Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program‏
670 ‎‡a Author's Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B.‏
670 ‎‡a Author's High prevalence of pulmonary tuberculosis but low sensitivity of symptom screening among HIV-infected pregnant women in South Africa‏
670 ‎‡a Author's HIV and tuberculosis in prisons in sub-Saharan Africa.‏
670 ‎‡a Author's HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa‏
670 ‎‡a Author's HIV testing services in healthcare facilities in South Africa: a missed opportunity‏
670 ‎‡a Author's Household HIV Testing Uptake among Contacts of TB Patients in South Africa‏
670 ‎‡a Author's Human leukocyte antigen associations with protection against tuberculosis infection and disease in human immunodeficiency virus-1 infected individuals, despite household tuberculosis exposure and immune suppression‏
670 ‎‡a Author's Immune recovery after starting ART in HIV-infected patients presenting and not presenting with tuberculosis in South Africa‏
670 ‎‡a Author's Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors‏
670 ‎‡a Author's Implementation and Operational Research: Risk Charts to Guide Targeted HIV-1 Viral Load Monitoring of ART: Development and Validation in Patients From Resource-Limited Settings‏
670 ‎‡a Author's Implementing a large-scale systematic tuberculosis screening program in correctional facilities in South Africa‏
670 ‎‡a Author's Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation‏
670 ‎‡a Author's Including the criminal justice-involved at the HIV policy, research and service delivery table.‏
670 ‎‡a Author's Isoniazid Preventive Therapy and Pregnancy Outcomes In HIV-Infected Women in the Tshepiso Cohort‏
670 ‎‡a Author's Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies‏
670 ‎‡a Author's Life expectancy trends in adults on antiretroviral treatment in South Africa‏
670 ‎‡a Author's Maternal hepatitis B and infant infection among pregnant women living with HIV in South Africa‏
670 ‎‡a Author's Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis‏
670 ‎‡a Author's Mortality associated with delays between clinic entry and ART initiation in resource-limited settings: results of a transition-state model‏
670 ‎‡a Author's Observational study of continuity of HIV care following release from correctional facilities in South Africa‏
670 ‎‡a Author's Plasma Indoleamine 2, 3-Dioxygenase, a Biomarker for Tuberculosis in Human Immunodeficiency Virus-Infected Patients‏
670 ‎‡a Author's Pooling sputum from multiple individuals for Xpert® MTB/RIF testing: a strategy for screening high-risk populations.‏
670 ‎‡a Author's Poor Obstetric and Infant Outcomes in HIV-Infected Pregnant Women with Tuberculosis in South Africa: The Tshepiso Study‏
670 ‎‡a Author's Prevalence and associations with hepatitis B and hepatitis C infection among HIV-infected adults in South Africa.‏
670 ‎‡a Author's Psychological distress among recent Russian immigrants in the United States‏
670 ‎‡a Author's Psychometric properties of a Russian version of the SF-12 Health Survey in a refugee population‏
670 ‎‡a Author's Rationale and evidence for human immunodeficiency virus treatment as prevention at the individual and population levels‏
670 ‎‡a Author's Readmission and death following hospitalization among people with HIV in South Africa‏
670 ‎‡a Author's Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa‏
670 ‎‡a Author's Reducing tuberculosis-associated mortality among people with HIV‏
670 ‎‡a Author's Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa‏
670 ‎‡a Author's Simultaneous Treatment of Missing Data and Measurement Error in HIV Research Using Multiple Overimputation‏
670 ‎‡a Author's Strategies to Accelerate HIV Care and Antiretroviral Therapy Initiation After HIV Diagnosis: A Randomized Trial‏
670 ‎‡a Author's Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies‏
670 ‎‡a Author's Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa‏
670 ‎‡a Author's The HIV/HBV co-infected patient: Time for proactive management‏
670 ‎‡a Author's The Next Battleground for Patient Safety: Influenza Immunization of Healthcare Workers‏
670 ‎‡a Author's Thyroid function abnormalities in HIV-infected patients‏
670 ‎‡a Author's Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa‏
670 ‎‡a Author's Tuberculosis active case finding: uptake and diagnostic yield among minibus drivers in urban South Africa‏
670 ‎‡a Author's Tuberculosis and hepatic steatosis are prevalent liver pathology findings among HIV-infected patients in South Africa‏
670 ‎‡a Author's Value stream mapping to characterize value and waste associated with accessing HIV care in South Africa‏
670 ‎‡a Author's Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa‏
670 ‎‡a Author's Zidovudine impairs immunological recovery on first-line antiretroviral therapy: collaborative analysis of cohort studies in southern Africa‏
909 ‎‡a (scopus) 35310450700‏ ‎‡9 1‏
909 ‎‡a (orcid) 0000000294220519‏ ‎‡9 1‏
919 ‎‡a hivandtuberculosisinprisonsinsubsaharanafrica‏ ‎‡A HIV and tuberculosis in prisons in sub-Saharan Africa.‏ ‎‡9 1‏
919 ‎‡a hivsuppressionwithstavudine30mgversus40mginadultsover60kgonantiretroviraltherapyinsouthafrica‏ ‎‡A HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa‏ ‎‡9 1‏
919 ‎‡a hivtestingservicesinhealthcarefacilitiesinsouthafricaamissedopportunity‏ ‎‡A HIV testing services in healthcare facilities in South Africa: a missed opportunity‏ ‎‡9 1‏
919 ‎‡a householdhivtestinguptakeamongcontactsoftbpatientsinsouthafrica‏ ‎‡A Household HIV Testing Uptake among Contacts of TB Patients in South Africa‏ ‎‡9 1‏
919 ‎‡a humanleukocyteantigenassociationswithprotectionagainsttuberculosisinfectionanddiseaseinhumanimmunodeficiencyvirus1infectedindividualsdespitehouseholdtuberculosisexposureandimmunesuppression‏ ‎‡A Human leukocyte antigen associations with protection against tuberculosis infection and disease in human immunodeficiency virus-1 infected individuals, despite household tuberculosis exposure and immune suppression‏ ‎‡9 1‏
919 ‎‡a hepatotoxicityinanafricanantiretroviraltherapycohorttheeffectoftuberculosisandhepatitisb‏ ‎‡A Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B.‏ ‎‡9 1‏
919 ‎‡a hepatitisbvirusinfectionandresponsetoantiretroviraltherapyartinasouthafricanartprogram‏ ‎‡A Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program‏ ‎‡9 1‏
919 ‎‡a hepatitisbvirusinfectionandresponsetoantiretroviraltherapy‏ ‎‡A Hepatitis B virus infection and response to antiretroviral therapy‏ ‎‡9 1‏
919 ‎‡a hepatitisbprevalenceandtreatmentneedsamongtibetanrefugeesresidinginindia‏ ‎‡A Hepatitis B prevalence and treatment needs among Tibetan refugees residing in India.‏ ‎‡9 1‏
919 ‎‡a immunerecoveryafterstartingartinhivinfectedpatientspresentingandnotpresentingwithtuberculosisinsouthafrica‏ ‎‡A Immune recovery after starting ART in HIV-infected patients presenting and not presenting with tuberculosis in South Africa‏ ‎‡9 1‏
919 ‎‡a hepatitisbinfectionviralloadandresistanceinhivinfectedpatientsinmozambiqueandzambia‏ ‎‡A Hepatitis B Infection, Viral Load and Resistance in HIV-Infected Patients in Mozambique and Zambia‏ ‎‡9 1‏
919 ‎‡a hepatitisbandlongtermhivoutcomesincoinfectedhaartrecipients‏ ‎‡A Hepatitis B and long-term HIV outcomes in coinfected HAART recipients‏ ‎‡9 1‏
919 ‎‡a impactofdrugresistanceassociatedaminoacidchangesinhiv1subtype100onsusceptibilitytonewernonnucleosidereversetranscriptaseinhibitors‏ ‎‡A Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors‏ ‎‡9 1‏
919 ‎‡a genderdifferencesinsurvivalamongadultpatientsstartingantiretroviraltherapyinsouthafricaamulticentrecohortstudy‏ ‎‡A Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study‏ ‎‡9 1‏
919 ‎‡a futureofhivaidscareinlowandmiddleincomecountries‏ ‎‡A Future of HIV/AIDS Care in Low- and Middle- Income Countries‏ ‎‡9 1‏
919 ‎‡a implementationandoperationalresearchriskchartstoguidetargetedhiv1viralloadmonitoringofartdevelopmentandvalidationinpatientsfromresourcelimitedsettings‏ ‎‡A Implementation and Operational Research: Risk Charts to Guide Targeted HIV-1 Viral Load Monitoring of ART: Development and Validation in Patients From Resource-Limited Settings‏ ‎‡9 1‏
919 ‎‡a 4modelsofhivcounselingandtestingutilizationandtestresultsinsouthafrica‏ ‎‡A Four models of HIV counseling and testing: utilization and test results in South Africa‏ ‎‡9 1‏
919 ‎‡a feasibilityofimplementingsamedayantiretroviraltherapyinitiationduringroutinecareinekurhulenidistrictsouthafricaretentionandviralloadsuppression‏ ‎‡A Feasibility of implementing same-day antiretroviral therapy initiation during routine care in Ekurhuleni District, South Africa: Retention and viral load suppression‏ ‎‡9 1‏
919 ‎‡a implementingalargescalesystematictuberculosisscreeningprogramincorrectionalfacilitiesinsouthafrica‏ ‎‡A Implementing a large-scale systematic tuberculosis screening program in correctional facilities in South Africa‏ ‎‡9 1‏
919 ‎‡a factorsassociatedwithpulmonaryimpairmentinhivinfectedsouthafricanadults‏ ‎‡A Factors associated with pulmonary impairment in HIV-infected South African adults‏ ‎‡9 1‏
919 ‎‡a factorsassociatedwithpoorlinkagetohivcareinsouthafricasecondaryanalysisofdatafromthetholimpilotrial‏ ‎‡A Factors Associated With Poor Linkage to HIV Care in South Africa: Secondary Analysis of Data From the Thol'impilo Trial‏ ‎‡9 1‏
919 ‎‡a incidenceandriskfactorsforhepatocellularcarcinomaaftersolidorgantransplantation‏ ‎‡A Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation‏ ‎‡9 1‏
919 ‎‡a evaluationofapointofcaretuberculosistestandtreatalgorithmonearlymortalityinpeoplewithhivaccessingantiretroviraltherapytbfasttrackstudystudyprotocolforaclusterrandomisedcontrolledtrial‏ ‎‡A Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): study protocol for a cluster randomised controlled trial‏ ‎‡9 1‏
919 ‎‡a includingthecriminaljusticeinvolvedatthehivpolicyresearchandservicedeliverytable‏ ‎‡A Including the criminal justice-involved at the HIV policy, research and service delivery table.‏ ‎‡9 1‏
919 ‎‡a isoniazidpreventivetherapyandpregnancyoutcomesinhivinfectedwomeninthetshepisocohort‏ ‎‡A Isoniazid Preventive Therapy and Pregnancy Outcomes In HIV-Infected Women in the Tshepiso Cohort‏ ‎‡9 1‏
919 ‎‡a lifeexpectanciesofsouthafricanadultsstartingantiretroviraltreatmentcollaborativeanalysisofcohortstudies‏ ‎‡A Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies‏ ‎‡9 1‏
919 ‎‡a lifeexpectancytrendsinadultsonantiretroviraltreatmentinsouthafrica‏ ‎‡A Life expectancy trends in adults on antiretroviral treatment in South Africa‏ ‎‡9 1‏
919 ‎‡a maternalhepatitisbandinfantinfectionamongpregnantwomenlivingwithhivinsouthafrica‏ ‎‡A Maternal hepatitis B and infant infection among pregnant women living with HIV in South Africa‏ ‎‡9 1‏
919 ‎‡a monitoringandswitchingof1lineantiretroviraltherapyinadulttreatmentcohortsinsubsaharanafricacollaborativeanalysis‏ ‎‡A Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis‏ ‎‡9 1‏
919 ‎‡a epidemiologyoftuberculosisandhivrecentadvancesinunderstandingandresponses‏ ‎‡A Epidemiology of tuberculosis and HIV: recent advances in understanding and responses‏ ‎‡9 1‏
919 ‎‡a mortalityassociatedwithdelaysbetweenclinicentryandartinitiationinresourcelimitedsettingsresultsofatransitionstatemodel‏ ‎‡A Mortality associated with delays between clinic entry and ART initiation in resource-limited settings: results of a transition-state model‏ ‎‡9 1‏
919 ‎‡a effectiveinterpersonalhealthcommunicationforlinkagetocareafterhivdiagnosisinsouthafrica‏ ‎‡A Effective Interpersonal Health Communication for Linkage to Care After HIV Diagnosis in South Africa‏ ‎‡9 1‏
919 ‎‡a durablehivrnaresuppressionaftervirologicfailurewhileremainingona1lineregimenacohortstudy‏ ‎‡A Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study‏ ‎‡9 1‏
919 ‎‡a diagnosticaccuracyofplasmakynureninetryptophanratiomeasuredbyenzymelinkedimmunosorbentassayforpulmonarytuberculosis‏ ‎‡A Diagnostic accuracy of plasma kynurenine/tryptophan ratio, measured by enzyme-linked immunosorbent assay, for pulmonary tuberculosis‏ ‎‡9 1‏
919 ‎‡a cotrimoxazoleprophylaxisandtuberculosisriskamongpeoplelivingwithhiv‏ ‎‡A Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV.‏ ‎‡9 1‏
919 ‎‡a comparisonoftenofovirzidovudineorstavudineaspartof1lineantiretroviraltherapyinaresourcelimitedsettingacohortstudy‏ ‎‡A Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study‏ ‎‡9 1‏
919 ‎‡a clinicalimplicationsofhivandhepatitisbcoinfectioninasiaandafrica‏ ‎‡A Clinical implications of HIV and hepatitis B co-infection in Asia and Africa‏ ‎‡9 1‏
919 ‎‡a chronichepatitisbincreasesmortalityandcomplexityamonghivcoinfectedpatientsinsouthafricaacohortstudy‏ ‎‡A Chronic hepatitis B increases mortality and complexity among HIV-coinfected patients in South Africa: a cohort study.‏ ‎‡9 1‏
919 ‎‡a observationalstudyofcontinuityofhivcarefollowingreleasefromcorrectionalfacilitiesinsouthafrica‏ ‎‡A Observational study of continuity of HIV care following release from correctional facilities in South Africa‏ ‎‡9 1‏
919 ‎‡a plasmaindoleamine23dioxygenaseabiomarkerfortuberculosisinhumanimmunodeficiencyvirusinfectedpatients‏ ‎‡A Plasma Indoleamine 2, 3-Dioxygenase, a Biomarker for Tuberculosis in Human Immunodeficiency Virus-Infected Patients‏ ‎‡9 1‏
919 ‎‡a poolingsputumfrommultipleindividualsforxpertmtbriftestingastrategyforscreeninghighriskpopulations‏ ‎‡A Pooling sputum from multiple individuals for Xpert® MTB/RIF testing: a strategy for screening high-risk populations.‏ ‎‡9 1‏
919 ‎‡a poorobstetricandinfantoutcomesinhivinfectedpregnantwomenwithtuberculosisinsouthafricathetshepisostudy‏ ‎‡A Poor Obstetric and Infant Outcomes in HIV-Infected Pregnant Women with Tuberculosis in South Africa: The Tshepiso Study‏ ‎‡9 1‏
919 ‎‡a changingpredictorsofmortalityovertimefromcartstartimplicationsforcare‏ ‎‡A Changing predictors of mortality over time from cART start: implications for care‏ ‎‡9 1‏
919 ‎‡a prevalenceandassociationswithhepatitisbandhepatitis100infectionamonghivinfectedadultsinsouthafrica‏ ‎‡A Prevalence and associations with hepatitis B and hepatitis C infection among HIV-infected adults in South Africa.‏ ‎‡9 1‏
919 ‎‡a cd4countslopeandmortalityinhivinfectedpatientsonantiretroviraltherapymulticohortanalysisfromsouthafrica‏ ‎‡A CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa‏ ‎‡9 1‏
919 ‎‡a psychologicaldistressamongrecentrussianimmigrantsintheunitedstates‏ ‎‡A Psychological distress among recent Russian immigrants in the United States‏ ‎‡9 1‏
919 ‎‡a psychometricpropertiesofarussianversionofthesf12healthsurveyinarefugeepopulation‏ ‎‡A Psychometric properties of a Russian version of the SF-12 Health Survey in a refugee population‏ ‎‡9 1‏
919 ‎‡a cd4countbasedfailurecriteriacombinedwithviralloadmonitoringmaytriggerworseswitchdecisionsthanviralloadmonitoringalone‏ ‎‡A CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.‏ ‎‡9 1‏
919 ‎‡a rationaleandevidenceforhumanimmunodeficiencyvirustreatmentaspreventionattheindividualandpopulationlevels‏ ‎‡A Rationale and evidence for human immunodeficiency virus treatment as prevention at the individual and population levels‏ ‎‡9 1‏
919 ‎‡a associationofisoniazidpreventivetherapywithlowerearlymortalityinindividualsonantiretroviraltherapyinaworkplaceprogramme‏ ‎‡A Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme‏ ‎‡9 1‏
919 ‎‡a readmissionanddeathfollowinghospitalizationamongpeoplewithhivinsouthafrica‏ ‎‡A Readmission and death following hospitalization among people with HIV in South Africa‏ ‎‡9 1‏
919 ‎‡a antiretroviraltherapyusingzidovudinelamivudineandefavirenzinsouthafricatolerabilityandclinicalevents‏ ‎‡A Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events‏ ‎‡9 1‏
919 ‎‡a reducingmortalitywithcotrimoxazolepreventivetherapyatinitiationofantiretroviraltherapyinsouthafrica‏ ‎‡A Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa‏ ‎‡9 1‏
919 ‎‡a novelhivtreatmentmodelusingprivatepractitionersinsouthafrica‏ ‎‡A A novel HIV treatment model using private practitioners in South Africa‏ ‎‡9 1‏
919 ‎‡a reducingtuberculosisassociatedmortalityamongpeoplewithhiv‏ ‎‡A Reducing tuberculosis-associated mortality among people with HIV‏ ‎‡9 1‏
919 ‎‡a frameworktoinformstrategiestoimprovethehivcarecontinuuminlowandmiddleincomecountries‏ ‎‡A A Framework to Inform Strategies to Improve the HIV Care Continuum in Low- and Middle-Income Countries‏ ‎‡9 1‏
919 ‎‡a resistancetotenofovirbasedregimensduringtreatmentfailureofsubtype100hiv1insouthafrica‏ ‎‡A Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa‏ ‎‡9 1‏
919 ‎‡a simultaneoustreatmentofmissingdataandmeasurementerrorinhivresearchusingmultipleoverimputation‏ ‎‡A Simultaneous Treatment of Missing Data and Measurement Error in HIV Research Using Multiple Overimputation‏ ‎‡9 1‏
919 ‎‡a strategiestoacceleratehivcareandantiretroviraltherapyinitiationafterhivdiagnosisarandomizedtrial‏ ‎‡A Strategies to Accelerate HIV Care and Antiretroviral Therapy Initiation After HIV Diagnosis: A Randomized Trial‏ ‎‡9 1‏
919 ‎‡a comparisonofdeathrecordingbyhealthcentresandcivilregistrationinsouthafricansreceivingantiretroviraltreatment‏ ‎‡A A comparison of death recording by health centres and civil registration in South Africans receiving antiretroviral treatment‏ ‎‡9 1‏
919 ‎‡a tenofovirin2lineartinzambiaandsouthafricacollaborativeanalysisofcohortstudies‏ ‎‡A Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies‏ ‎‡9 1‏
919 ‎‡a tenofovirorzidovudinein2lineantiretroviraltherapyafterstavudinefailureinsouthernafrica‏ ‎‡A Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa‏ ‎‡9 1‏
919 ‎‡a hivhbvcoinfectedpatienttimeforproactivemanagement‏ ‎‡A The HIV/HBV co-infected patient: Time for proactive management‏ ‎‡9 1‏
919 ‎‡a nextbattlegroundforpatientsafetyinfluenzaimmunizationofhealthcareworkers‏ ‎‡A The Next Battleground for Patient Safety: Influenza Immunization of Healthcare Workers‏ ‎‡9 1‏
919 ‎‡a thyroidfunctionabnormalitiesinhivinfectedpatients‏ ‎‡A Thyroid function abnormalities in HIV-infected patients‏ ‎‡9 1‏
919 ‎‡a treatmentfailuredrugresistanceandcd4tcellcountdeclineamongpostpartumwomenonantiretroviraltherapyinsouthafrica‏ ‎‡A Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa‏ ‎‡9 1‏
919 ‎‡a tuberculosisactivecasefindinguptakeanddiagnosticyieldamongminibusdriversinurbansouthafrica‏ ‎‡A Tuberculosis active case finding: uptake and diagnostic yield among minibus drivers in urban South Africa‏ ‎‡9 1‏
919 ‎‡a tuberculosisandhepaticsteatosisareprevalentliverpathologyfindingsamonghivinfectedpatientsinsouthafrica‏ ‎‡A Tuberculosis and hepatic steatosis are prevalent liver pathology findings among HIV-infected patients in South Africa‏ ‎‡9 1‏
919 ‎‡a valuestreammappingtocharacterizevalueandwasteassociatedwithaccessinghivcareinsouthafrica‏ ‎‡A Value stream mapping to characterize value and waste associated with accessing HIV care in South Africa‏ ‎‡9 1‏
919 ‎‡a viremiaresuppressionandtimetoresistanceinhumanimmunodeficiencyvirushivsubtype100during1lineantiretroviraltherapyinsouthafrica‏ ‎‡A Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa‏ ‎‡9 1‏
919 ‎‡a zidovudineimpairsimmunologicalrecoveryon1lineantiretroviraltherapycollaborativeanalysisofcohortstudiesinsouthernafrica‏ ‎‡A Zidovudine impairs immunological recovery on first-line antiretroviral therapy: collaborative analysis of cohort studies in southern Africa‏ ‎‡9 1‏
919 ‎‡a highprevalenceofpulmonarytuberculosisbutlowsensitivityofsymptomscreeningamonghivinfectedpregnantwomeninsouthafrica‏ ‎‡A High prevalence of pulmonary tuberculosis but low sensitivity of symptom screening among HIV-infected pregnant women in South Africa‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 DNB|129057328X‏
996 ‎‡2 DNB|1052876684‏
996 ‎‡2 ISNI|0000000014673864‏
996 ‎‡2 DNB|1052514367‏
996 ‎‡2 DNB|1157496725‏
996 ‎‡2 DNB|1132542545‏
996 ‎‡2 ISNI|0000000396155850‏
996 ‎‡2 ISNI|0000000016099114‏
996 ‎‡2 DNB|1155756371‏
996 ‎‡2 DNB|173478824‏
996 ‎‡2 DNB|120539772‏
996 ‎‡2 DNB|1212042085‏
996 ‎‡2 ISNI|0000000393482880‏
996 ‎‡2 SUDOC|224270990‏
996 ‎‡2 LC|n 82049944‏
996 ‎‡2 NLA|000035398260‏
996 ‎‡2 NUKAT|n 2010130533‏
996 ‎‡2 DNB|135558581‏
996 ‎‡2 ISNI|0000000001656256‏
996 ‎‡2 ISNI|0000000081357693‏
996 ‎‡2 DNB|1030495610‏
996 ‎‡2 LC|n 00091282‏
996 ‎‡2 DNB|116940336‏
996 ‎‡2 LC|n 00093624‏
996 ‎‡2 J9U|987007262723305171‏
996 ‎‡2 NTA|432958754‏
996 ‎‡2 BIBSYS|7048004‏
996 ‎‡2 NSK|000583021‏
996 ‎‡2 RERO|A014104900‏
996 ‎‡2 DNB|143338854‏
996 ‎‡2 LC|no2019181535‏
996 ‎‡2 LC|no2015164377‏
996 ‎‡2 ISNI|0000000394000302‏
996 ‎‡2 NUKAT|n 2015139558‏
996 ‎‡2 LC|n 2013002171‏
996 ‎‡2 DNB|118552457‏
996 ‎‡2 DNB|142787299‏
996 ‎‡2 DNB|137596731‏
996 ‎‡2 NUKAT|n 2018045982‏
996 ‎‡2 NTA|068871740‏
996 ‎‡2 DNB|1052876994‏
996 ‎‡2 J9U|987007285221905171‏
996 ‎‡2 DNB|143754130‏
996 ‎‡2 NTA|170621634‏
996 ‎‡2 DNB|115757856X‏
996 ‎‡2 DNB|1031680829‏
996 ‎‡2 NKC|ntk20221162314‏
996 ‎‡2 SUDOC|076348423‏
996 ‎‡2 ISNI|0000000071006558‏
996 ‎‡2 LC|n 97126478‏
996 ‎‡2 DNB|1103163957‏
996 ‎‡2 ISNI|0000000016063592‏
996 ‎‡2 J9U|987007349260905171‏
996 ‎‡2 LC|no2005064508‏
996 ‎‡2 DE633|pe30010061‏
996 ‎‡2 DNB|1175892262‏
996 ‎‡2 DNB|1030449759‏
996 ‎‡2 DNB|137600097‏
996 ‎‡2 NTA|18186097X‏
996 ‎‡2 NII|DA11808361‏
996 ‎‡2 DNB|142998699‏
996 ‎‡2 DNB|116936967‏
996 ‎‡2 DNB|118058347‏
996 ‎‡2 ISNI|0000000384033944‏
996 ‎‡2 DNB|1167716744‏
996 ‎‡2 PTBNP|1200623‏
996 ‎‡2 PLWABN|9810695778205606‏
996 ‎‡2 DNB|122538560‏
996 ‎‡2 ISNI|0000000108826171‏
996 ‎‡2 DE633|pe30014828‏
996 ‎‡2 LC|no 99004314‏
996 ‎‡2 DE633|pe30022288‏
996 ‎‡2 NTA|182327493‏
996 ‎‡2 DNB|1041848331‏
996 ‎‡2 SUDOC|26791542X‏
996 ‎‡2 RERO|A018493239‏
996 ‎‡2 RERO|A003377232‏
996 ‎‡2 ISNI|000000042516743X‏
996 ‎‡2 DNB|1271067560‏
996 ‎‡2 NKC|nlk20000089215‏
996 ‎‡2 SZ|116940336‏
996 ‎‡2 DNB|121016048‏
996 ‎‡2 DNB|1035076691‏
996 ‎‡2 RERO|A013203302‏
996 ‎‡2 BNF|12292024‏
996 ‎‡2 NTA|127000143‏
996 ‎‡2 DNB|139584013‏
996 ‎‡2 NUKAT|n 01715483‏
996 ‎‡2 DNB|124816630‏
996 ‎‡2 DNB|141826800‏
996 ‎‡2 DNB|142315478‏
996 ‎‡2 BNF|16650896‏
996 ‎‡2 J9U|987007364029105171‏
996 ‎‡2 NTA|354885782‏
996 ‎‡2 DNB|1192024001‏
996 ‎‡2 DNB|1079917284‏
996 ‎‡2 DNB|122204034‏
996 ‎‡2 RERO|A017011369‏
996 ‎‡2 ISNI|0000000013559410‏
996 ‎‡2 LC|no 92033410‏
996 ‎‡2 DNB|122873203‏
996 ‎‡2 DNB|1266017534‏
996 ‎‡2 DNB|1214676340‏
996 ‎‡2 BIBSYS|12015511‏
996 ‎‡2 NUKAT|n 2007278232‏
996 ‎‡2 ISNI|0000000081239996‏
996 ‎‡2 DBC|87097969986870‏
996 ‎‡2 SUDOC|243654367‏
996 ‎‡2 ISNI|0000000079713230‏
996 ‎‡2 DNB|100358616‏
996 ‎‡2 DNB|1067649719‏
996 ‎‡2 NTA|073661740‏
996 ‎‡2 DNB|1102256595‏
996 ‎‡2 PLWABN|9810695127005606‏
996 ‎‡2 RERO|A006436866‏
996 ‎‡2 NII|DA07812128‏
996 ‎‡2 BNF|10501864‏
996 ‎‡2 NTA|308444604‏
996 ‎‡2 NUKAT|n 2021088310‏
996 ‎‡2 DNB|1282609971‏
996 ‎‡2 SUDOC|185716474‏
996 ‎‡2 SUDOC|266733948‏
996 ‎‡2 BAV|495_323397‏
996 ‎‡2 DNB|1024192954‏
996 ‎‡2 PLWABN|9810662191405606‏
996 ‎‡2 DNB|108003773X‏
996 ‎‡2 NUKAT|n 2013180544‏
996 ‎‡2 RERO|A013302918‏
996 ‎‡2 NUKAT|n 2013010893‏
996 ‎‡2 DNB|130288993‏
996 ‎‡2 SUDOC|219433542‏
996 ‎‡2 DNB|1026089719‏
996 ‎‡2 LIH|LNB:B,MH;=0L‏
996 ‎‡2 DNB|1161559582‏
996 ‎‡2 BAV|495_323388‏
996 ‎‡2 DNB|1211008487‏
996 ‎‡2 DNB|1138651850‏
996 ‎‡2 PLWABN|9812831472805606‏
996 ‎‡2 LIH|LNB:V-152063;=BD‏
996 ‎‡2 SUDOC|08590600X‏
996 ‎‡2 RERO|A003377211‏
996 ‎‡2 DNB|119712016‏
996 ‎‡2 DNB|1089696507‏
996 ‎‡2 CAOONL|ncf11339993‏
996 ‎‡2 ISNI|0000000397961862‏
996 ‎‡2 DNB|1051413974‏
996 ‎‡2 SUDOC|073681164‏
996 ‎‡2 DNB|1192277678‏
996 ‎‡2 DNB|1140251961‏
996 ‎‡2 RERO|A028135386‏
996 ‎‡2 BIBSYS|98074059‏
996 ‎‡2 LC|no2008145788‏
996 ‎‡2 DNB|1037597230‏
996 ‎‡2 SUDOC|160592348‏
996 ‎‡2 ISNI|000000039998788X‏
996 ‎‡2 RERO|A026590357‏
996 ‎‡2 DNB|1157794882‏
996 ‎‡2 ISNI|0000000072948539‏
996 ‎‡2 DNB|1175705098‏
996 ‎‡2 DNB|130268844‏
996 ‎‡2 NTA|108947459‏
996 ‎‡2 NUKAT|n 2011066848‏
996 ‎‡2 DNB|122204018‏
996 ‎‡2 BNF|16725369‏
996 ‎‡2 RERO|A024394889‏
996 ‎‡2 DNB|1051825245‏
996 ‎‡2 ISNI|0000000066415306‏
996 ‎‡2 DNB|174093586‏
996 ‎‡2 BNC|981058512942106706‏
996 ‎‡2 DNB|131464051‏
996 ‎‡2 DNB|1195089309‏
996 ‎‡2 DNB|122778812‏
996 ‎‡2 DNB|103764395X‏
996 ‎‡2 ISNI|0000000425166592‏
996 ‎‡2 DNB|1244546593‏
996 ‎‡2 NII|DA01875963‏
996 ‎‡2 DNB|1157840523‏
996 ‎‡2 SZ|130268844‏
996 ‎‡2 DNB|124437095‏
996 ‎‡2 LC|n 90614939‏
996 ‎‡2 RERO|A024308811‏
996 ‎‡2 DNB|1230905715‏
996 ‎‡2 ISNI|0000000066839571‏
996 ‎‡2 DNB|1019261382‏
996 ‎‡2 DNB|1205477527‏
996 ‎‡2 BAV|495_56137‏
996 ‎‡2 NUKAT|n 2009117756‏
996 ‎‡2 DNB|1126756172‏
996 ‎‡2 RERO|A009356484‏
996 ‎‡2 DNB|1025436164‏
996 ‎‡2 LC|n 87884719‏
996 ‎‡2 DNB|1072835320‏
996 ‎‡2 DNB|1157576893‏
996 ‎‡2 DNB|129045128‏
996 ‎‡2 DNB|139264329‏
996 ‎‡2 BIBSYS|90209846‏
996 ‎‡2 DNB|132761033‏
996 ‎‡2 J9U|987007372257905171‏
996 ‎‡2 NUKAT|n 97066950‏
996 ‎‡2 DNB|1243851775‏
996 ‎‡2 DE633|pe41014126‏
996 ‎‡2 NKC|jo2014827808‏
996 ‎‡2 DNB|173215874‏
996 ‎‡2 SUDOC|15935157X‏
996 ‎‡2 ISNI|0000000107764909‏
996 ‎‡2 J9U|987007444534305171‏
996 ‎‡2 DNB|143094076‏
996 ‎‡2 DNB|1037647998‏
996 ‎‡2 DNB|1327873613‏
996 ‎‡2 DNB|120584905X‏
996 ‎‡2 NTA|069955379‏
996 ‎‡2 DNB|130111317‏
996 ‎‡2 DNB|1017162328‏
996 ‎‡2 PLWABN|9810611153605606‏
996 ‎‡2 DNB|119712024‏
996 ‎‡2 NUKAT|n 2014141665‏
996 ‎‡2 DNB|1052486967‏
996 ‎‡2 LC|no2024017282‏
996 ‎‡2 LC|nr2001050169‏
996 ‎‡2 DE633|pe30041278‏
996 ‎‡2 BIBSYS|2133213‏
996 ‎‡2 DNB|1052489303‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏